TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Spectral Medical ( (TSE:EDT) ) has shared an update.
Spectral Medical announced positive results from its Phase 3 Tigris trial, which demonstrated significant survival benefits for patients with endotoxic septic shock using its PMX treatment. The company is preparing for a Premarket Approval submission to the FDA, now targeted for Q1 2026, and is collaborating with Vantive on commercialization efforts. This progress positions Spectral for a strong market entry and potential FDA approval, which could significantly impact its operations and market positioning.
The most recent analyst rating on (TSE:EDT) stock is a Hold with a C$1.50 price target. To see the full list of analyst forecasts on Spectral Medical stock, see the TSE:EDT Stock Forecast page.
Spark’s Take on TSE:EDT Stock
According to Spark, TipRanks’ AI Analyst, TSE:EDT is a Neutral.
The overall stock score is primarily impacted by significant financial challenges, including consistent losses and negative cash flows. While technical indicators show positive momentum, the negative P/E ratio and lack of dividend yield highlight valuation concerns. The absence of earnings call insights and corporate events limits additional context.
To see Spark’s full report on TSE:EDT stock, click here.
More about Spectral Medical
Spectral Medical Inc. is a late-stage theranostic company that focuses on advancing therapeutic options for sepsis and septic shock. The company is engaged in the development of PMX, a treatment for endotoxic septic shock, and is actively working on its commercialization and regulatory approval.
Average Trading Volume: 177,130
Technical Sentiment Signal: Buy
Current Market Cap: C$413.5M
For detailed information about EDT stock, go to TipRanks’ Stock Analysis page.